In vitro effects of 3′-azido-3′-deoxythymidine (AZT) on normal human polymorphonuclear cell and monocyte-macrophage functional capacities

Immunopharmacology and Immunotoxicology

Volumn 18, Issue 2, 1996, Pages 161-178

  De Simone, C ^a   Maffione, A B ^b   Calvello, R ^b   Nacci, C ^d   Sciannameo, G ^d   Greco, B ^d   Caradonna, L ^d   Pece, S ^d   Antonaci, S ^b   Jirillo, E ^c  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c POLICLINICO   (Italy)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ADULT; ARTICLE; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; MALE; MONOCYTE; NEUTROPHIL; PHAGOCYTOSIS; PRIORITY JOURNAL;

ADULT; CELLS, CULTURED; FEMALE; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; NEUTROPHILS; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0029891533     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.3109/08923979609052730     Document Type: Article

References (50)

1. Barre-Sinoussi, F., Chermann, J.C., Rey, F. et al., Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS), Science, 220: 868, 1983.
2. Gallo, R.C., Sarin, P.S., Gelmann, E.P. et al., Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS), Science, 220: 865, 1983.
3. Dalgleish, A.G., Beverly, P.C.L., Clapman, P.R.et al., The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus, Nature, 312: 763, 1984.
4. Klatzman, D., Champagne, E., Charmaret, S.et al., T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV, Nature, 312: 767, 1984.
5. Maddon, P.J., Dalgleish, A.G., McDougal, J.S. et al., The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain, Cell, 47: 333, 1986.
6. - cells by a complex of the 110 K viral protein and the T4 molecule, Science, 231: 382, 1986.
7. Lane, H.C. and Fauci, A.S., Immunologic abnormalities in the acquired immunodeficiency syndrome, Annu. Rev. Immunol., 3: 477, 1985.
8. Bowen, D.L., Lane, H.C. and Fauci, A.S., Immunopathogenesis of the acquired immunodeficiency syndrome, Ann. Intern. Med., 103: 704, 1985.
9. Lazzarin, A., Uberti Foppa, C., Galli, M., et al., Impairment of polymorphonuclear leucocyte function in patients with acquired immunodeficiency syndrome and with lymphadenopathy syndrome, Clin. Exp. Immunol., 65: 105, 1986.
10. Klebanoff, S.J. and Coombs, R.W., Viricidal effect of polymorphonuclear leukocytes on human immunodeficiency Virus-1, J. Clin. Invest., 89: 2014, 1992.
11. Biggs, B.-A., Hewish, M., Kent, S., et al., HIV-1 infection of human macrophages impairs phagocytosis and killing of Toxoplasma gondii, J. Immunol., 154: 6132, 1995.
12. Crowle, A.J., Ross, E.R., Cohn, D.L., et al., Comparison of the abilities of Mycobacterum avium and Mycobacterium intracellulare to infect and multiply in cultured human macrophages from normal and human immunodeficiency virus-infected subjects, Infect. and Immun., 60: 3697, 1992.
13. Newman, G.W., Kelley, T. G., Gan, H., et al., Concurrent infection of human macrophages with HIV-1 and Mycobacterium avium results in decreased cell viability, increased M. Avium multiplication and altered cytokine production, J. Immunol., 151: 2261, 1993
14. Muller, F., Rollag, H. and Froland, S.S., Reduced oxidative burst responses in monocytes and monocyte-derived macrophages from HIV-infected subjects, Clin Exp. Immunol., 82: 10, 1990.
15. Schuitemaker, H., Kootstra, N.A., Koppelman, M.H.G.M., et al., Proliferation-dependent HIV-1 infection of monocytes occurs during differentiation into macrophages, J. Clin. Invest., 89: 1154, 1992.
16. Antonaci, S., Jirillo, E., Stasi, D. et al., Immunoresponsiveness in hemophilia: lymphocyte and phagocyte-mediated functions, Diagn. and Clin. Immunol., 5: 318, 1988
17. Mitsuya, H., Weinhold, K.J., Furman, P.A. et al., 3′-azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro, Proc. Natl. Acad. Sci. USA, 82: 7096, 1985.
18. Balzarini, J., Pauwels, R., Baba, M. et al., The in vitro and in vivo antiretrovirus activity, and intracellular metabolism of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell species, Biochem. Pharmacol., 37: 897, 1988.
19. Nakashima, H., Matsui, T., Harada, S. et al., Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type II/lymphadenopathy-associated virus by 3′-azido-3′-deoxythymidine in vitro. Antimicrob. Agents Chemother., 30: 933, 1986.
20. Mitchell, W.M., Montefiori, D.C., Robinson, W.E. Jr. et al., Mismatched double-stranded RNA (ampligen) reduces concentration of zidovudine (azidothymidine) required for in vitro inhibition of human immunodeficiency virus, Lancet, 1: 890, 1987.
21. Hammer, S.M. and Gillis, J.M., Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3′-azido-3′-deoxythymidine against human immunodeficiency virus in vitro. Antimicrob. Agents chemoter., 31: 1046, 1987.
22. Richman, D.D., Dideoxynucleosides are less inhibitory in vitro against human immunodeficiency virus type 2 (HIV-2) than against HIV-1, Antimicrob. Agents Chemother., 31 1879, 1987.
23. Yarchoan, R., Klecker, R.W., Weinhold, K.J. et al., Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or ALDS-Related Complex, Lancet, 1: 575, 1986.
24. Furman, P.A., Fyfe, J.A., St. Clair, M.H., et al., Phosphorylation of 3′-azido-3′deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficency virus reverse transcriptase, Proc. Natl. Acad. Sc. USA, 83: 8333, 1986.
25. Richman, D.D., Kornbluth, R.S., Carson, D.A., Failure of dideoxynucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages, J. Exp. Med., 166: 1144, 1987.
26. Gallicchio, V.S., Hughes, N.K., Tse, K-F et al., Effect of combination interleukin-1 and erythropoietin in ameliorating the hematopoietic toxicity associated with the use of zidovudine administered to normal mice, Life Sci., 54: 351, 1994.
27. Volberding, P.A., Lagakos, S.W., Koch, M.A. et al., Zidovudine in asymptomatic human immunodeficiency virus infection, N. Engl. J. Med., 322:941, 1990.
28. Fischl M.A., Richman D.D., Causey D.M., et al., Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex, J. Am. Med. Assoc., 262: 2405, 1989.
29. Hamilton, J.D., Hartigan, P.M., Simberkoff, M.S., et al., A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection, N. Engl. J. Med., 326: 437, 1992.
30. Levy, E.M., Wu, J., Cohn, S.E. et al., Increased T-cell colony formation in AIDS patients treated with zidovudine: A possible mechanism for increased lymphocyte number, AIDS, 3:605, 1989.
31. Gerding, M.N., Schuurman, H.J., Bast B.J.E.G. et al., Lymphocytes' intrinsic lymphoproliferative capacity in patients with AIDS treated with zidovudine, AIDS, 3:671, 1989.
32. McMahon, D.K., Winkelstein, A., Armstrong, J.A. et al., Zidovudine therapy is associated with an increased capacity of phytohemagglutinin-stimulated cells to express interleukin-2 receptors, AIDS, 5:491, 1991.
33. Rinaldo, C., Huang, Z.L., Piazza, P., et al., Augmentation of cellular immune function during the early phase of zidovudine treatment of AIDS patients, J. Infect. Dis., 164:638, 1991.
34. - T cell anti-HIV activity, Clin. Immunol. Immunopathol., 73:80, 1994.
35. Boyum, A., Isolation of mononuclear cells and granulocytes from human blood, Scand. J. Clin. Lab. Invest., 21 (suppl. 97): 77, 1968.
36. Hondalus, M.K., Moiser, D.M., Survival and replication of Rhodococcus equi in macrophages, Infect. Immun., 62: 4167, 1994.
37. Haston, W. S and Shields, J. M., Neutrophil leucocyte chemotaxis: a simplified assay for measuring polarizing responses to chemotactic factors, J. Immunol. Methods, 81: 229, 1985.
38. Weening, R. S., Wever, R and Ross, D., Quantitative aspects of the production of superoxide radicals by phagocitizing human granulocytes, J. Lab. Clin. Med., 85: 245, 1975.
39. Pick, E. and Keisari, Y. J., A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture, J. Immunol. Methods, 38: 161, 1980.
40. Mandell, L., Hook, W.E., Leukocyte function in chronic granulomatous diseases of childhood, Am. J. Med., 47: 473, 1969.
41. Edelson, P.J., Intracellular parasites and phagocytic cells: cell biology and pathophysiology, Rev. Infect. Dis., 4: 124, 1982.
42. Ezehowitz, R.A.B., Sim, R.B., Hill, M. et al., Local opsonization by secreted macrophage complement components: role of receptors for complement in uptake of zymosan, J. Exp. Med., 159: 244, 1983.
43. Sung, S.S., Nelson, R.S., Silverstein, S.C., Yeast mannans inhibit binding and phagocytosis of zymosan by mouse peritoneal macrophages, J. Cell Biol., 96: 160, 1983.
44. Hondalus, M.K., Diamond, M.S., Rosenthal, L.A., et al., The intracellular bacterium Rhodococcus equi requires Mac-1 to bind to mammalian cells, Infect. Immun. 61: 2919, 1993.
45. Jirillo, E., Covelli, V., Maffione, A.B., et al., Endotoxin, cytokines and neuroimmune networks with special reference to HIV infection, Ann. N. Y. Acad. Sci. USA, 741: 174, 1994
46. Jirillo, E., Pellegrino, N.M. and Antonaci, S., Role of tumor necrosis factor-α in physiological and pathological conditions, Med. Sci. Res., 25: 75, 1995.
47. Matsuyama, T., Kobayashi, N., Yamamoto, N., Cytokines and HIV infection: is AIDS a tumor necrosis factor disease?, AIDS, 5: 1405, 1991.
48. Poli, G. Vicenzi, E., Ghezzi, S. et al., Cytokines in the acquired immunodeficiency syndrome and other infectious disease, Int. J. Clin. Lab., 25: 128, 1995.
49. Maffione, A.B., Calvello, R., Greco, B., et al., E., LPS and related cytokines (CKs) in HIV-infected patients: in vitro role of zidovudine, J. Endotox. Res., 1 (suppl. 1): 38, 1994.
50. Elwell, L. P., Ferone, R., Freeman, G. A., et al., Antibacterial activity and mechanism of action of 3′-azido-3′-deoxythymidine (BW A5509U), Antimicrob. Agens Chemother., 31: 274, 1987.